SecBot SecBot
8-K ·Filed May 6, 2026

BCRX

BIOCRYST PHARMACEUTICALS INC
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001171843-26-003052
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The maintained guidance and solid ORLADEYO growth (+21% ex-Europe) are reassuring, but the stock is unlikely to move sharply on in-line results. The key catalyst to watch is the completion of navenibart Phase 3 enrollment by end of June 2026, which would de-risk the pipeline. The $70M upfront licensing deal provides a near-term cash buffer. Traders should monitor for any enrollment updates or guidance changes on the Q2 2026 earnings call.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.83
T+0 close · May 6, 2026 · via day close
Latest settled
+1.70%
T+60 · $8.98
Vs SPY
−0.36%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 6 $8.83entry
  2. T+1 · 6mo ago +0.79%α +1.12% · $8.90
  3. T+5 · 6mo ago −0.34%α −1.47% · $8.80
  4. T+20 · 6mo ago −6.57%α −9.35% · $8.25
  5. T+60 · 4mo ago +1.70%α −0.36% · $8.98

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioCryst reported Q1 2026 ORLADEYO revenue of $148.3M (+11% y-o-y; +21% on a comparable ex-Europe basis), in line with the maintained FY2026 guidance of $625-645M. The GAAP net loss of $721.8M was driven by a $697.8M non-cash charge from the Astria acquisition, but non-GAAP operating profit was $54.2M. The company also announced a $70M upfront licensing deal for European navenibart rights, with up to $275M in milestones. Guidance was maintained, and the navenibart Phase 3 enrollment is on track to complete by June 2026.

Key Financial Metrics

Revenue
$156.4M
est $151.1M · +3.5% · +7.5% YoY
Guidance
$635M-$660M
maintained

Key Facts

  • Q1 2026 ORLADEYO net revenue $148.3M, +11% reported y-o-y, +21% on a comparable basis excluding European revenue
  • GAAP net loss of $721.8M driven by $697.8M non-cash acquired IPR&D charge from Astria acquisition
  • Non-GAAP operating profit of $54.2M in Q1 2026
  • Full-year 2026 ORLADEYO revenue guidance maintained at $625M-$645M; total revenue guidance maintained at $635M-$660M
  • Licensing agreement with Neopharmed Gentili for European navenibart rights: $70M upfront, up to $275M milestones, plus 18%-30% tiered royalties
  • Navenibart Phase 3 ALPHA-ORBIT enrollment on track to complete by end of June 2026; regulatory filing targeted by end of 2027
  • Cash, equivalents, restricted cash and investments at March 31, 2026: $260.8M; pro-forma including post-quarter-end $70M license proceeds: $330.8M
  • Company ended development of avoralstat (DME program) in Q1 2026
  • Appointed Sandeep M. Menon as Chief Research and Development Officer in April 2026

Financial Impact

Q1 ORLADEYO revenue of $148.3M was in line with the maintained $625-645M annual guidance run-rate. The $70M upfront from the navenibart licensing deal strengthens the balance sheet.

revenuecashoperating profit

Risk Factors

  • Navenibart is still in Phase 3 and unapproved; regulatory or clinical setbacks could impair the $697.8M IPR&D asset
  • GAAP net loss of $721.8M and accumulated deficit of $2.23B highlight ongoing cash burn despite non-GAAP profitability
  • Secured term loan of $395.2M and royalty financing obligation of $447.5M represent significant leverage
  • Competition in HAE from injectable therapies (Takhzyro, Haegarda) could pressure ORLADEYO growth

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001171843-26-003052
Document: f8k_050626.htm0001171843-26-003052
Document: 0001171843-26-003052-index-headers.html0001171843-26-003052
Document: 0001171843-26-003052-index.html0001171843-26-003052
Document: 0001171843-26-003052.txt0001171843-26-003052
8-K Data (Synthetic)0001171843-26-003052

Track record

20 reports on BCRX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.01% at T+20 after the Feb 26, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.71 Now $7.45 −3.35% settles Feb 16
  2. Nov 13, 20263d ago Press Release Neutral 3/10 Entry $7.61 Now $7.45 −2.10% settles Feb 11
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $7.53 Now $7.45 −1.06% settles Feb 8
  4. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  5. Nov 4, 202612d ago Press Release Bullish 6/10 Entry $8.24 Now $7.45 −9.59% settles Feb 2
  6. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $8.57 Now $7.45 −13.07% settles Feb 1
  7. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $8.37 Now $7.45 −10.99% settles Jan 26
  8. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $7.78 Now $7.45 −4.24% settles Jan 20
  9. Aug 5, 202614w ago 8-K Bullish 7/10 Entry $9.07 to $8.46 Now $7.45 −17.86% ▼ −6.73% −6.92% vs SPY
  10. Jun 29, 202620w ago 8-K Neutral 5/10 Entry $9.55 to $8.78 Now $7.45 −21.99% ▼ −8.06% −12.45% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026